<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05126953</url>
  </required_header>
  <id_info>
    <org_study_id>21-003</org_study_id>
    <nct_id>NCT05126953</nct_id>
  </id_info>
  <brief_title>2-Hour Dispensing Evaluation of Samfilcon A Lenses With EPG01 Packaging Solution Compared to Commercially Available B+L Ultra Lenses</brief_title>
  <official_title>2-Hour Dispensing Evaluation of Samfilcon A Lenses With EPG01 Packaging Solution Compared to Commercially Available B+L Ultra Lenses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this 2 hour study is to evaluate the clinical performance of samfilcon A&#xD;
      lenses with an alternate packaging solution (EPG01) compared to commercially available B+L&#xD;
      Ultra lenses.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 21, 2021</start_date>
  <completion_date type="Actual">September 23, 2021</completion_date>
  <primary_completion_date type="Actual">September 23, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Normalized logMAR Visual Acuity</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Contact Lens Wearer</condition>
  <arm_group>
    <arm_group_label>samfilcon A Lenses with EPG01 Packaging Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B+L Ultra Lenses</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>samfilcon A Lenses with EPG01 Packaging Solution</intervention_name>
    <description>samfilcon A Lenses with EPG01 Packaging Solution</description>
    <arm_group_label>samfilcon A Lenses with EPG01 Packaging Solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>B+L Ultra Lenses</intervention_name>
    <description>Commercially available Biotrue ONEday lenses</description>
    <arm_group_label>B+L Ultra Lenses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be 18 years or older on the date the Informed Consent Form (ICF) is signed and have&#xD;
             capacity to read, understand and provide written voluntary informed consent.&#xD;
&#xD;
          2. Have physiologically normal anterior segments not exhibiting clinically significant&#xD;
             biomicroscopy findings.&#xD;
&#xD;
          3. Have no active ocular disease or allergic conjunctivitis.&#xD;
&#xD;
          4. Not be using any topical ocular medications.&#xD;
&#xD;
          5. Be willing and able to follow instructions.&#xD;
&#xD;
          6. Have signed a statement of informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participating in a conflicting study in the opinion of the Investigator.&#xD;
&#xD;
          2. Considered by the Investigator to not be a suitable candidate for participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffery Schafer, OD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bausch and Lomb Site 01</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 10, 2021</study_first_submitted>
  <study_first_submitted_qc>November 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

